Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Pathology

Recognizing Symptoms and Securing an Accurate Diagnosis

At a Glance

AL amyloidosis is diagnosed by recognizing unique symptoms like an enlarged tongue or eye bruising, followed by a tissue biopsy. The biopsy must be stained with Congo red to confirm amyloid presence and strictly typed using mass spectrometry to ensure the correct targeted treatment.

Diagnosing AL amyloidosis is often a process of “connecting the dots.” Because the condition is rare and can mimic more common diseases, it is frequently missed in its early stages [1]. Understanding the specific symptoms and the rigorous testing required for an accurate diagnosis is the first step toward getting the right treatment [2].

The “Red Flag” Symptoms

AL amyloidosis can affect almost any organ, but there are several hallmark signs that should immediately raise suspicion [3]. If you are experiencing these, it is vital to discuss them with a specialist:

  • Macroglossia (Enlarged Tongue): The tongue may become visibly larger, sometimes showing indentations from the teeth along its edges. This is highly specific to AL amyloidosis [4][5].
  • Periorbital Purpura (“Raccoon Eyes”): This is unexplained bruising around the eyes that can appear after minor trauma, such as sneezing or coughing. It occurs because amyloid deposits make the small blood vessels fragile [3][4].
  • Nephrotic-Range Proteinuria: This is a sign of kidney involvement where the kidneys leak large amounts of protein into the urine. You might notice “foamy” urine or significant swelling (edema) in your legs and ankles [3][6].
  • Heart Failure with Preserved Ejection Fraction (HFpEF): You may have symptoms of heart failure—like shortness of breath and fatigue—even though a standard heart test (echocardiogram) shows your heart is still pumping “normally.” In amyloidosis, the heart becomes stiff rather than weak, making it hard for it to fill with blood [7][8].

The Gold Standard: Biopsy and Congo Red

To officially diagnose amyloidosis, a doctor must physically see the amyloid deposits [9]. This requires a tissue biopsy. This is often done by taking a small sample of fat from the abdomen (a fat pad aspirate) or by biopsying an affected organ like the kidney or heart [10][11].

Important Note: AL amyloidosis can occasionally cause an acquired bleeding risk (Factor X deficiency), so you should ensure your care team checks your blood’s ability to clot before any invasive procedures [12].

The tissue is treated with a special dye called Congo red stain. When viewed under a microscope with polarized light, amyloid deposits glow with a very specific “apple-green birefringence” [9][13]. If this green glow is present, it confirms that amyloid is there—but it does not tell the doctor which type of amyloid it is [13][14].

Why “Typing” the Amyloid is Non-Negotiable

Confirming the presence of amyloid is only half the battle. There are many types of amyloidosis, and they are treated very differently. The most common “look-alike” is ATTR amyloidosis, which is a completely different disease [15].

Mass Spectrometry is the gold standard for “typing” or identifying the specific protein in the amyloid [16][17]. It is much more accurate than older methods like immunohistochemistry (IHC), which can sometimes give unclear or even wrong results [18][19].

Feature AL Amyloidosis ATTR Amyloidosis
Source Plasma cells (Bone Marrow) Liver protein (Transthyretin)
Treatment Chemotherapy / Immunotherapy Protein stabilizers / Silencers
Risk of Error High if typing is not done High if typing is not done

Getting the type wrong means you could receive toxic chemotherapy for a disease that doesn’t respond to it, or miss out on life-saving treatment for the disease you actually have [15][17]. Always ensure your biopsy was typed using mass spectrometry.

Common questions in this guide

What are the early symptoms of AL amyloidosis?
Hallmark warning signs include an enlarged tongue (macroglossia), unexplained bruising around the eyes (raccoon eyes), foamy urine due to kidney damage, and heart failure symptoms like shortness of breath and fatigue. Because it is rare, these symptoms are often mistaken for more common conditions.
How is AL amyloidosis officially diagnosed?
Diagnosis requires a tissue biopsy, usually taken from abdominal fat or an affected organ. The tissue is treated with a special Congo red stain, which makes amyloid deposits glow an apple-green color when viewed under a polarized microscope.
Why is mass spectrometry important for my biopsy?
Confirming you have amyloidosis is only the first step; doctors must identify the exact protein causing it. Mass spectrometry is the most accurate test for this 'typing' process. Getting the right type is critical because different forms of the disease, like AL and ATTR, require completely different treatments.
Can AL amyloidosis cause bleeding problems?
Yes, AL amyloidosis can occasionally cause an acquired bleeding risk known as Factor X deficiency. Because of this risk, your medical team should always check your blood's ability to clot before performing any invasive procedures or biopsies.
Why do I have heart failure symptoms if my echocardiogram is normal?
In amyloidosis, protein deposits build up in the heart muscle, making it stiff rather than weak. This causes a condition where the heart pumps normally but cannot relax and fill with blood properly, leading to heart failure symptoms despite a 'normal' echocardiogram reading.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was my tissue biopsy 'typed' using mass spectrometry, or was only immunohistochemistry used?
  2. 2.If my Congo red stain was positive, how did you definitively confirm that the protein is 'AL' and not another type like 'ATTR'?
  3. 3.Has my blood been checked for an acquired bleeding risk, such as Factor X deficiency, before we do any invasive procedures?
  4. 4.Based on my tests, which of my organs are officially considered 'involved' by the disease?
  5. 5.Is an abdominal fat pad biopsy enough for my case, or do I need a biopsy of a specific organ like my heart or kidney?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Healthcare resource utilisation and costs associated with AL amyloidosis: a retrospective matched cohort study.

    Shen SP, Hou HA, Huang KC, et al.

    Scientific reports 2024; (14(1)):16915 doi:10.1038/s41598-024-65654-5.

    PMID: 39043721
  2. 2

    Amyloidosis of the Heart and Kidney.

    Adrogue HE

    Methodist DeBakey cardiovascular journal 2022; (18(4)):27-33 doi:10.14797/mdcvj.1150.

    PMID: 36132587
  3. 3

    Massive Hepatomegaly Secondary to Amyloidosis with Normal Liver Chemistries.

    Doe-Williams S, Hixson LJ, Pfeiffer DC

    Case reports in gastroenterology 2020; (14(2)):271-278 doi:10.1159/000507612.

    PMID: 32518538
  4. 4

    Macroglossia as the initial presentation of AL amyloidosis: review and updates in treatment.

    Cherico AS, Rizvi A, Jayakrishnan T, Mewawalla P

    BMJ case reports 2022; (15(7)) doi:10.1136/bcr-2022-249737.

    PMID: 35817492
  5. 5

    Case report of amyloid light-chain amyloidosis with periocular cutaneous involvement

    Haász C, Kuroli E, Anker P, et al.

    Orvosi hetilap 2021; (162(32)):1303-1308 doi:10.1556/650.2021.32137.

    PMID: 34370685
  6. 6

    Renal Involvement in Systemic Amyloidosis Caused by Monoclonal Immunoglobulins.

    Karam S, Leung N

    Hematology/oncology clinics of North America 2020; (34(6)):1069-1079 doi:10.1016/j.hoc.2020.08.002.

    PMID: 33099424
  7. 7

    An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib-based chemotherapy.

    Gibbons A, Chakravorty L, Sidiqi H, et al.

    Internal medicine journal 2026; (56(4)):582-588 doi:10.1111/imj.70335.

    PMID: 41724702
  8. 8

    Electrocardiographic parameters and prognosis of renal light chain amyloidosis.

    Li H, Wang Y, Lan P, et al.

    Clinical cardiology 2020; (43(10)):1160-1166 doi:10.1002/clc.23426.

    PMID: 33460229
  9. 9

    Extensive amyloid deposits in bone marrow aspirate smears.

    Li THS, Wong KF, Wong WS

    Clinical case reports 2020; (8(12)):3581-3582 doi:10.1002/ccr3.3236.

    PMID: 33363988
  10. 10

    Detection yield of surrogate tissue biopsies across amyloidosis classes: a large-scale analysis of 4,027 patients.

    Burke NJ, Mendelson LM, Joshi T, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2025; 1-9 doi:10.1080/13506129.2025.2606847.

    PMID: 41460224
  11. 11

    Evaluation of abdominal fat pad aspiration highlighting challenges to interpretation.

    Torous VF, Chebib I

    Journal of the American Society of Cytopathology 2024; (13(3)):219-226 doi:10.1016/j.jasc.2024.01.003.

    PMID: 38493005
  12. 12

    Thrombotic and bleeding complications in patients with AL amyloidosis.

    Fotiou D, Theodorakakou F, Spiliopoulou S, et al.

    British journal of haematology 2024; (204(5)):1816-1824 doi:10.1111/bjh.19331.

    PMID: 38321638
  13. 13

    Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients.

    Tasaki M, Milani P, Foli A, et al.

    Blood 2019; (134(3)):320-323 doi:10.1182/blood.2019000420.

    PMID: 31171502
  14. 14

    Confirming the Diagnosis of Amyloidosis.

    Wisniowski B, Wechalekar A

    Acta haematologica 2020; (143(4)):312-321 doi:10.1159/000508022.

    PMID: 32544917
  15. 15

    A Spatial Proteomics Approach to Isolate and Analyze Amyloid Proteins Using Laser Capture Microdissection and Mass Spectrometry.

    Aguilan J, Horton M, Pessin JE, Sidoli S

    Methods in molecular biology (Clifton, N.J.) 2026; (3015()):121-134 doi:10.1007/978-1-0716-5154-4_10.

    PMID: 41629715
  16. 16

    The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry.

    Gonzalez Suarez ML, Zhang P, Nasr SH, et al.

    Kidney international 2019; (96(4)):1005-1009 doi:10.1016/j.kint.2019.05.027.

    PMID: 31447055
  17. 17

    Renal amyloidosis: a new time for a complete diagnosis.

    Feitosa VA, Neves PDMM, Jorge LB, et al.

    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica 2022; (55()):e12284 doi:10.1590/1414-431X2022e12284.

    PMID: 36197414
  18. 18

    Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits.

    Abildgaard N, Rojek AM, Møller HE, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2020; (27(1)):59-66 doi:10.1080/13506129.2019.1688289.

    PMID: 31752543
  19. 19

    Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry.

    Mollee P, Boros S, Loo D, et al.

    Clinical proteomics 2016; (13()):30 doi:10.1186/s12014-016-9133-x.

    PMID: 27795698

This page explains AL amyloidosis symptoms and diagnostic testing for educational purposes. Always consult your hematologist or organ specialist for a definitive diagnosis and biopsy interpretation.

Get notified when new evidence is published on Primary systemic amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.